A Pilot Study of Glofitamab and Lenalidomide in People With Previously Treated Mantle Cell Lymphoma


Full Title

Pilot Study of Glofitamab and Lenalidomide in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with a BTK Inhibitor


Researchers are seeing how well the combination of glofitamab and lenalidomide works against lymphoma. The people in this study have mantle cell lymphoma (MCL) that keeps growing even after treatment. Their prior treatment included a drug called a BTK inhibitor.

Both glofitamab and lenalidomide strengthen the immune system’s ability to fight cancer cells. If you join this study, you will get glofitamab and lenalidomide after treatment with the standard MCL drug obinutuzumab. These medications are given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have MCL that keeps growing even though you got treatment with a BTK inhibitor.
  • Have recovered from the serious side effects of previous therapies before getting the study treatment.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Anita Kumar’s office at 646-608-3780.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID